

August 2012 - Rhenman Healthcare Equity L/S

Monthly Update

August was a month of slightly falling markets in anticipation of Fed's next step for stimulating the economy and the ECB's next package of measures to stabilize Spain's financial situation. The value of the Fund was stable and the main share class (IC1 EUR) ended unchanged, which was slightly better than many of the broad stock indices.

The election campaign in the US is in full swing and is evenly balanced between the Republicans and the Democrats. The economy, unemployment and healthcare are dominant themes. Healthcare reform divides the country into two parts: the Republicans believe that Obamacare is both too expensive and too bureaucratic while the Democrats believe that the country has to provide a certain degree of basic protection for all citizens, financed by health insurance that includes all. Republicans fear that the reform will be much more expensive than expected, whereas the Democrats, for their part, believe that it will be cheaper because synergies have not been taken into account. Drug Reform (free drugs for the country's pensioners who receive their care through managed care), which has been in existence for several years, was only approximately half as expensive for the general public as expected.

The election debate is however very emotionally charged but also factually confused. The Republican presidential candidate, Mitt Romney, implemented a reform in Massachusetts that is very similar to Obamacare. In actual fact, this reform is the model for Obamacare. Furthermore, the reform in Massachusetts has gone relatively well, something that is hard to ignore; the number of uninsured people is low and costs have been in line with costs for the whole country.

The discussion is therefore becoming increasingly ideologically loaded. Is the U.S. going to socialize healthcare? Or is this the most important and most significant reform since Lyndon Johnson introduced Medicare? Do politicians know what the economic consequences will be in the long run? Is the reform the beginning of significantly more limited access to healthcare for those who hitherto have had very good access?

The Fund suffered a major setback through our holding in Incyte which made a negative contribution to the Fund of nearly one percent. The company spoke cautiously about the second half of the year for their new cancer medicine (patients develop certain side-effects and tend to break off the treatment if the initial doses given are too high), and the market was very disappointed. However, the share has begun to stabilize. To our delight, we see that July's worst shares have stabilized and, in some cases, started to rise again. Mako Surgical is one such example. This is a common phenomenon; last month's losers are often next month's winners. We continue to hold a relatively large position in Incyte and note that the company management admits that forecasts are conservative.


We are very positive about the autumn but a certain cautious attitude will probably emerge in October in the run-up to the U.S. election. We believe that the outcome of the election will play a relatively small role for the Fund as a whole but affect our sub-sectors in slightly different ways. We are trying to hedge our bets by spreading our holdings so that the fund's development will be stable regardless of the election results.

Sarepta Therapeutics, Mako Surgical, and Threshold gave the largest positive contributions to the fund's development during the month. Exelixis, Incyte Corp and Aveo were the largest negative contributors.

Return IC1 (EUR)

	Rhenman Healthcare Equity L/S IC1 (EUR)	3 Month Euribor (EUR)
August	0.00%	0.06%
YTD	19.43%	0.65%
Since Inception (June 22, 2009)	60.74%	3.28%


Return IC1 (EUR)



Return RC1 (EUR)

	Rhenman Healthcare Equity L/S RC1 (EUR)	3 Month Euribor (EUR)
August	-0.04%	0.06%
YTD	19.14%	0.65%
Since Inception (August 31, 2010)	48.83%	2.29%


Return RC1 (EUR)



Return RC1 (SEK)

	Rhenman Healthcare Equity L/S RC1 (SEK)	3 Month Euribor (EUR)
August	-0.25%	0.06%
YTD	13.33%	0.65%
Since Inception (June 22, 2009)	25.85%	3.28%


Return RC1 (SEK)



Return RC2 (SEK)

	Rhenman Healthcare Equity L/S RC2 (SEK)	3 Month Euribor (EUR)
August	-0.21%	0.06%
YTD	13.52%	0.65%
Since Inception (June 22, 2009)	27.86%	3.28%

Return RC2 (SEK)



IC1 (EUR) NAV													
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	
2009						100.75	105.19	107.47	107.83	100.99	105.70	113.28	
2010	117.91	119.94	127.53	122.31	108.73	106.40	102.84	102.63	109.95	112.16	116.17	122.73	
2011	121.53	124.28	123.35	127.79	134.24	129.26	128.19	119.36	118.28	125.67	127.48	134.59	
2012	142.42	143.99	149.51	150.29	150.07	159.07	160.74	160.74					
IC1 (EUR) Performance %, net of fees													
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Total
2009						0.75	4.41	2.17	0.33	-6.34	4.66	7.17	+13.28
2010	4.09	1.72	6.33	-4.09	-11.10	-2.14	-3.35	-0.20	7.13	2.01	3.58	5.65	+8.34
2011	-0.98	2.26	-0.75	3.60	5.05	-3.71	-0.83	-6.89	-0.90	6.25	1.44	5.58	+9.66
2012	5.82	1.10	3.83	0.52	-0.15	6.00	1.05	0.00					+19.43
RC1 (EUR) NAV													
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	
2009													
2010								100.00	104.35	104.75	110.36	115.32	
2011	114.18	116.50	115.79	119.40	125.10	120.47	119.15	110.91	109.86	116.68	118.31	124.92	
2012	132.14	133.59	138.66	139.34	139.09	147.39	148.89	148.83					
RC1 (EUR) Performance %, net of fees													
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Total
2009													
2010									4.35	0.38	5.36	4.49	+15.32
2011	-0.99	2.03	-0.61	3.12	4.77	-3.70	-1.10	-6.92	-0.95	6.21	1.40	5.59	+8.32
2012	5.78	1.10	3.80	0.49	-0.18	5.97	1.02	-0.04					+19.14
RC1 (SEK) NAV													
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	
2009						99.74	99.92	101.00	101.51	96.72	101.85	106.75	
2010	110.70	108.05	115.09	109.18	96.69	93.87	89.69	88.93	93.37	96.59	98.29	102.16	
2011	98.91	100.22	101.80	105.28	111.04	109.04	107.03	100.09	100.29	104.24	106.42	111.05	
2012	118.78	118.87	123.79	125.05	125.79	130.61	126.17	125.85					
RC1 (SEK) Performance %, net of fees													
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Total
2009						-0.26	0.18	1.08	0.50	-4.72	5.30	4.81	+6.75
2010	3.70	-2.39	6.52	-5.14	-11.44	-2.92	-4.45	-0.85	4.99	3.45	1.76	3.94	-4.30
2011	-3.18	1.32	1.58	3.42	5.47	-1.80	-1.84	-6.48	0.20	3.94	2.09	4.35	+8.70
2012	6.96	0.08	4.14	1.02	0.59	3.83	-3.40	-0.25					+13.33
RC2 (SEK) NAV													
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	
2009						99.74	99.98	101.12	101.68	96.94	102.10	107.07	
2010	111.07	108.57	115.69	109.78	97.28	94.47	90.31	89.58	94.10	97.38	99.14	103.08	
2011	99.84	101.20	102.84	106.40	112.28	110.30	108.32	101.33	101.58	105.64	107.89	112.63	
2012	120.30	120.44	125.51	126.83	127.66	132.58	128.13	127.86					
RC2 (SEK) Performance %, net of fees													
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Total
2009						-0.26	0.24	1.14	0.55	-4.66	5.32	4.87	+7.07
2010	3.74	-2.25	6.56	-5.11	-11.39	-2.89	-4.40	-0.81	5.05	3.49	1.81	3.97	-3.73
2011	-3.14	1.36	1.62	3.46	5.53	-1.76	-1.80	-6.45	0.25	4.00	2.13	4.39	+9.26
2012	6.81	0.12	4.21	1.05	0.65	3.85	-3.36	-0.21					+13.52
Risk (IC1)			Exposure					Largest Long Positions					
Value at Risk, % ¹			2.2	Long				115%	Roche				
Standard deviation, % ^{2,3}			19.7	Short				11%	Incyte				
Sharpe ratio ^{2,3}			0.77	Gross				126%	Medtronic				
				Net				105%	Alkermes				
									Allscripts				

1) For holdings on August 31. 2) Since inception until August 31.

3) Standard deviation and Sharpe ratio annualized. 4) The exposure is adjusted for a substantial fund inflow at month end.

Currency Exposure (% of equity > 6%)					
USD	71%	EUR	11%	CHF	5%

Fund characteristics

- Target annual net returns in excess of 12% with a volatility below the stock market
- Long-term investment horizon but active trading around holdings
- Roughly equal allocation to small-, mid- and large-cap companies
- Typically 60–80 positions out of a 500 company universe
- Portfolio company size > USD 200 million
- Cash flow positive companies are predominant

Key Data

• Base currency:	EUR
• Subscription/redemption frequency:	Monthly (T-3)
• Share classes:	(R) Retail class / (I) Institutional class
• Minimum initial investment:	IC1 = EUR 250 000 RC1 = EUR 2 500, SEK 25 000 RC2 = SEK 2 500 000
• Minimum top-up investment:	No minimum
• Management fee:	IC1 = 1.5 %, RC1 = 2%, RC2 = 1.5 %
• Benchmark:	Euribor 90D
• Performance fee (quarterly):	20 % (high water mark)
• Soft close:	EUR 500m
• Hard close:	EUR 1bn
• Dividends:	R = Only capitalization I = Capitalization + Distribution
• Legal Structure:	Open-ended FCP (Fonds Commun de Placement) under Part II of the Luxembourg Law on Investment Funds (20 Dec, 2002)
• Fund Management Company:	SEB Fund Services S.A.
• Fund Promotor (Sponsor):	SEB Fund Services S.A.
• Investment Manager:	Rhenman & Partners Asset Management AB
• Placement and Distribution Agent:	Rhenman & Partners Asset Management AB
• Custodian Bank and Paying Agent:	Skandinaviska Enskilda Banken S.A.
• Prime Broker:	Skandinaviska Enskilda Banken AB (publ)
• External Auditor:	PricewaterhouseCoopers (PwC)
• Swedish registration:	Yes (since November 5, 2009)
• ISIN:	IC1 (EUR) = LU0417598108, RC1 (EUR) = LU0417597555 RC1 (SEK) = LU0417597712, RC2 (SEK) = LU0417598017
• Bloomberg ticker:	IC1 (EUR) = RHLIC1 LX, RC1 (EUR) = RHLERC1 LX RC1 (SEK) = RHLSRC1 LX, RC2 (SEK) = RHLSRC2 LX
• Lipper Reuters ticker:	IC1 (EUR) = 65147588, RC1 (EUR) = 65147589 RC1 (SEK) = 68014067, RC2 (SEK) = 68015239
• Telekurs ticker:	IC1 (EUR) = 10034579, RC1 (EUR) = 10034567 RC1 (SEK) = 10239523, RC2 (SEK) = 10239528

This material has been prepared for professional investors. Rhenman & Partners Asset Management AB (Rhenman & Partners) when preparing this report has not taken into account any one customer's particular investment objectives, financial resources or other relevant circumstances and the opinions and recommendations herein are not intended to represent recommendations of particular investments to particular customers. All securities' transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments and, in international transactions, currency risk. Due care and attention has been used in the preparation of this forecast information. However, actual results may vary from their forecasts, and any variation may be materially positive or negative. Forecasts, by their very nature, are subject to uncertainty and contingencies, many of which are outside the control of Rhenman & Partners. Rhenman & Partners cannot guarantee that the information contained herein is without fault or entirely accurate. The information in this material is based on sources that Rhenman & Partners believes to be reliable. Rhenman & Partners can however not guarantee that all information is correct. Furthermore, information and opinions may change without notice. Rhenman & Partners is under no obligation to make amendments or changes to this publication if errors are found or opinions or information change. Rhenman & Partners accepts no responsibility for the accuracy of its sources. Rhenman & Partners is the owner of all works of authorship including, but not limited to, all design, text, sound recordings, images and trademarks in this material unless otherwise explicitly stated. The use of Rhenman & Partners' material, works or trademarks is forbidden without written consent except where otherwise expressly stated. Furthermore, it is prohibited to publish material made or gathered by Rhenman & Partners without written consent.